Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
SHP2 (PTPN11) is a protein tyrosine phosphatase (PTP) containing two Src homology-2 domains (N-SH2, C-SH2), a PTP domain, and a carboxyl-terminal region.1 SHP2 is autoinhibited by the N-SH2 domain and PTP domain interaction in the basal state. In cancer cells, SHP2 is activated by oncogenic protein tyrosine kinases (PTKs) or gain-of-function (GOF) mutations. GOF SHP2 mutations also link to Noonan Syndrome (NS).2
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 3×
“SHP2 plays important roles in tumor growth [3, 4], in oncogenesis driven by PTK oncogenes such as FLT3-ITD in acute myeloid leukemia [5], and in immune checkpoints mediated by PD-1 or BTLA [6].”
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · cited 7×
“It was reported that SHP099 displayed the highest potency on slightly activated SHP2 by exposure to low concentrations of an activating peptide analog 2P-IRS-1 [10].”
InfluentialSelf-citationGarcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298 · cited 1×
“Recently, a novel allosteric SHP2 inhibitor (SHP099) was identified [9, 10].”
Self-citation
Cited by
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 237
“Indeed, it was recently demonstrated that several NS-causing SHP2 mutants are unfortunately resistant to the SHP2 allosteric inhibitor SHP099, although this molecule displayed high efficiency, good tolerance, and oral bioavailability (260).”
BackgroundKerr, D. L., Haderk, F., & Bivona, T. G. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.11.007 · Cited by 124
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
Valencia-Sama, I., Ladumor, Y., Kee, L., Adderley, T., Christopher, G., Robinson, C. M., Kano, Y., Ohh, M., & Irwin, M. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3822 · Cited by 62
Metadata
- Authors
- Sun, X., Ren, Y., Gunawan, S., Teng, P., Chen, Z., Lawrence, H., Cai, J., Lawrence, N., & Wu, J.
- Venue
- Leukemia
- Published
- 2018-01-30
- Volume
- 32
- Issue
- 5
- Pages
- 1246-1249
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2790214250
- Cited by
- 68
- References
- 3
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. https://app.cochat.ai/papers/10.1038/s41375-018-0020-5
- The paper
- Sun, X., Ren, Y., Gunawan, S., Teng, P., Chen, Z., Lawrence, H., Cai, J., Lawrence, N., & Wu, J. (2018). Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia. https://doi.org/10.1038/s41375-018-0020-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.